A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT03854227. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF-06939999 (PRMT5 INHIBITOR) IN PARTICIPANTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER, HEAD AND NECK SQUAMOUS CELL CARCINOMA, ESOPHAGEAL CANCER, ENDOMETRIAL CANCER, CERVICAL CANCER AND BLADDER CANCER
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 1, open label, multi center, dose escalation and expansion, safety, tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients with advanced or metastatic cancer.
Study identification
- NCT ID
- NCT03854227
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 54 participants
Conditions and interventions
Conditions
Interventions
- PF-06939999 dose escalation Drug
- PF-06939999 monotherapy Drug
- PF-06939999 in combination with docetaxel Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 14, 2019 (Actual)
- Primary completion
- Apr 27, 2022 (Actual)
- Completion
- Apr 27, 2022 (Actual)
- Last update posted
- Jan 13, 2025
2019 – 2022
United States locations
- U.S. sites
- 22
- U.S. states
- 8
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Scottsdale Healthcare Hospitals d/b/a HonorHealth | Scottsdale | Arizona | 85258 | — |
| Virginia G. Piper Cancer Pharmacy | Scottsdale | Arizona | 85258 | — |
| Keck Hospital of USC | Los Angeles | California | 90033 | — |
| LAC + USC Medical Center | Los Angeles | California | 90033 | — |
| USC Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| USC/Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| Keck Medical Center of USC Pasadena | Pasadena | California | 91105 | — |
| AdventHealth Celebration Infusion Center | Celebration | Florida | 34747 | — |
| AdventHealth Medical Group Oncology Research at Celebration | Celebration | Florida | 34747 | — |
| University Of Miami Hospital and Clinics/Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| AdventHealth Orlando - Investigational Drug Services | Orlando | Florida | 32804 | — |
| AdventHealth Orlando Infusion Center | Orlando | Florida | 32804 | — |
| AdventHealth Orlando | Orlando | Florida | 32804 | — |
| St. Joseph Mercy Hospital | Ann Arbor | Michigan | 48106 | — |
| St. Joseph Mercy Brighton | Brighton | Michigan | 48114 | — |
| Henry-Joyce Cancer Clinic | Nashville | Tennessee | 37232 | — |
| Oncology IDS Pharmacy | Nashville | Tennessee | 37232 | — |
| The University of Texas | Houston | Texas | 77030 | — |
| NEXT Oncology | San Antonio | Texas | 78229 | — |
| Inova Schar Cancer Institute | Fairfax | Virginia | 22031 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
| University of Washington Medical Center | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03854227, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 13, 2025 · Synced Oct 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03854227 live on ClinicalTrials.gov.